A study published in the Journal of Clinical Periodontology led by George Hajishengallis, Thomas W. Evans Centennial Professor in Penn’s School of Dental Medicine’s Department of Microbiology, and John D. Lambris, Dr. Ralph and Sallie Weaver Professor of Research Medicine in the Perelman School of Medicine’s Department of Pathology and […]
Amyndas Pharmaceuticals SA recently announced that its lead candidate, the C3 complement inhibitor AMY-101, has been granted orphan designation by the European Medicines Agency (EMA) and the U.S. FDA for the treatment of C3 glomerulopathy (C3G). Specifically, AMY-101 is the first drug to be granted an orphan drug status by […]
The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas’ lead candidate AMY-101, as a novel treatment for paroxysmal nocturnal hemoglobinuria (PNH). The AA&MDSIF has awarded Dr. Risitano (Federico II University) and Dr. Calado (University of Sao Paolo) a grant to fund the first clinical […]
A recent press release on the Penn Medicine News Blog explains a study which “further support[s] the concept that complement inhibition at the level of C3 rather than C5 will hopefully confer better therapeutic benefits for PNH patients because it will prevent destruction of red blood cells both inside and outside of vessels.” Such a therapeutic possibility is compstatin, a C3 inhibitor drug in development that was recently licensed by Amyndas Pharmaceuticals. Clinical trials for the resulting drug candidate are set for 2015 and 2016.To read entire press release: news.pennmedicine.org
A new review article titled ”A complement C3-targeted complement inhibitor reaching its prime for bedside intervention” by Mastellos et al., has been accepted for publication in the European Journal of Clinical Investigation. The review analyzes why complement component C3 represents an attractive target for therapeutic modulation of the complement cascade and describes in detail the optimization effort which has led to the structure-function refinement of compstatin and its novel derivatives such as AMY-101, with improved inhibitory potency, pharmacokinetic profile and efficacy in a number of clinically relevant primate models of disease. The review discusses translational challenges in complement drug discovery and peptide drug development and analyzes concerns related to systemic C3 interception; despite existing challenges AMY-101 emerges as a highly promising complement inhibitor therapeutic.
As a winner in the 2015 “Innovation Project” organised by the Association of Pharmaceutical Companies in Greece, Amyndas enjoys significant exposure in the local press and media in Greece. The science news source from two Greek Sunday newspapers, Kathimerini (November 16, 2014) and Makedonia (November 23, 2014) posted an informative profile of Amyndas, describing the company’s novel technology licensed from the Universiy of Penn, the wide range of potential therapeutic applications and the profound impact that these new therapies can have for patients and health care systems internationally. The articles (in Greek) created significant reader’s interest and can be accessed at: http://www.kathimerini.com.cy/index.php?pageaction=kat&modid=1&artid=189465&show=Y (newspaper Kathimerini) and http://www.makthes.gr/news/reportage/129900/ (newspaper Makedonia).
The “Innovation Project” is an open call competition organized by the Association of Pharmaceutical Companies in Greece, designed for small companies, spin-offs, entrepreneurs and researchers in the sector of pharmaceutical and bioscience innovation in Greece. The competition is sponsored by a group of large pharmaceutical companies active in the Greek market (Abbvie, Pharmaserve-Lilly, MSD, Novartis, Roche, Pharmathen, Chiesi and Genesis). The competition aims at strengthening the business capabilities of small companies, entrepreneurs and researchers, with pioneering ideas and innovative proposals in the biosciences, pharmaceutical and healthcare sector, while promoting extroversion and the competitive presence of these emerging players in the international markets. Amyndas entered this 2-stage competition and won a prize for “Original Pharmaceutical Innovation”. In addition to the monetary award Amyndas is eligible to receive a range of supportive services, such as advice on small company development, on regulatory and clinical development, as well on raising funds, or gain access to training centers and R & D. For the original article in Greek, click here.
“Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The U.S. FDA orphan designation comes after the European Medicines Agency (EMA) orphan status approval of AMY-101 for the same indication, less than 2 months ago.”
ΒΗΜΑ Science, the science news source from Greek Sunday newspaper BHMA, on September 7, 2014, posted an extended and informative interview of Amyndas pharmaceuticals founder, Prof John Lambris. In this article, which aimed at communicating the results of Prof Lambris’ scientific research to the public, Amyndas’ promising new drugs and their potential therapeutic applications are presented for the first time in a widely-read national Greek newspaper, conveying the profound impact that these new therapies can have for patients and health care systems internationally. The article created significant interest, with its wide readers’ audience commending and responding enthusiastically, hoping that these new therapies to be brought to patients soon. The article can be accessed here.
EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor. Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria. – PR12364497